| BELLUS Health is a clinical-stage biopharmaceutical company. Co.'s primary drug candidate is BLU-5937, being developed for the treatment of chronic cough. In preclinical studies, BLU-5937 exhibited an anti-tussive effect without affecting taste perception and a safety profile. BLU-5937 has the potential to be therapeutic for chronic cough patients who do not respond to existing therapies. The Phase 1 data demonstrated that BLU-5937 has a tolerability profile, as well as a pharmacokinetic profile supporting twice-a-day dosing. Co. has obtained from NEOMED Institute an exclusive worldwide license to develop and commercialize BLU-5937. We show 3 historical shares outstanding datapoints in our BLU shares outstanding history coverage, used to compute BLU market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing BLU market cap history over the course of time is important for investors
interested in comparing BLU's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of BLU versus a peer is one thing; comparing
BLU market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like BLU can fluctuate over the course of history.
With this page we aim to empower investors researching BLU by allowing them to research the BLU market cap history.